Absci

About:

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Website: https://www.absci.com

Twitter/X: abscibio

Top Investors: Fidelity, Perceptive Advisors, Oregon Venture Fund, Casdin Capital, aMoon Fund

Description:

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Total Funding Amount:

$324M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vancouver, Washington, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)absci.com

Founders:

Sean McClain

Number of Employees:

101-250

Last Funding Date:

2024-02-27

IPO Status:

Public

© 2024 MyAiNote.com